Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma

被引:193
作者
Gilks, C. Blake [1 ,6 ]
Ionescu, Diana N. [1 ,6 ]
Kalloger, Steve E. [1 ,6 ]
Koebel, Martin [1 ,2 ,6 ]
Irving, Julie [1 ,6 ]
Clarke, Blaise [1 ,6 ]
Santos, Jennifer [3 ,4 ]
Le, Nhu [5 ]
Moravan, Veronika [5 ]
Swenerton, Kenneth [3 ,4 ]
机构
[1] British Columbia Canc Agcy, Gynecol Tumour Grp, Vancouver, BC V5Z 4E3, Canada
[2] Charite Hosp, Inst Pathol, D-10117 Berlin, Germany
[3] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada
[4] British Columbia Canc Agcy, Gynecol Tumour Grp, Vancouver, BC V5Z 4E6, Canada
[5] British Columbia Canc Agcy, Vancouver, BC V5Z 1L3, Canada
[6] Vancouver Gen Hosp, Dept Pathol, Prostate Res Ctr, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 4E3, Canada
关键词
ovarian cancer; cell type; grade; prognosis;
D O I
10.1016/j.humpath.2008.01.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ovarian surface epithelial carcinomas are routinely subclassified by pathologists based on tumor cell type and grade. It is controversial whether cell type or grade is superior in predicting patient response to treatment or survival, in patients stratified by stage of disease. The aim of this study was to uniformly apply updated criteria for cell-type and grade assignment to a series of 575 cases of ovarian surface epithelial carcinoma. All patients were optimally surgically debulked, with no macroscopic residual disease after primary surgery. Slides from these cases were reviewed by a single pathologist, who was blinded to patient outcomes. In 50 cases, 2 additional pathologists reviewed the slides independently to determine interobserver variation in assessment of cell type and grade. The distribution of tumor stage was as follows: stage I-233 cases, stage II-246 cases, stage III-96 cases. The most common cell type encountered was serous carcinoma (229/575, 40%), followed by clear cell (149/575, 26%), endometrioid (139/575, 24%), and mucinous (36/575, 6%). Serous carcinomas were significantly more likely to present with advanced stage disease (76/229 [33.2%] were stage III, and 82% of all stage HI tumors were serous), whereas all nonserous cell types were stage I or II at diagnosis in greater than 90% of cases. Both FIGO grade and Silverberg grade stratified patients into groups with significantly different risks of relapse and survival, but the Silverberg grading system was a more powerful prognosticator. In multivariate analysis, stage was the most powerful prognostic indicator (P < .0001), followed by tumor cell type (P = .015), but grade was not of independent significance. Interobserver variation in assignment of cell type was very good (K = 0.77) with moderate reproducibility in assignment of Silverberg grade (kappa = 0.40) and minimal reproducibility in assignment of FIGO grade (kappa = 0.27). Thus, in this series of cases of ovarian surface epithelial carcinomas with no macroscopic residual disease after primary debulking surgery, assignment of tumor cell type was both more reproducible and provided superior prognostic information compared with assignment of tumor grade. As tumor cell type also correlates with underlying molecular abnormalities and may predict response to chemotherapy, this suggests that tumor cell type could be used to guide treatment decisions for patients with ovarian surface epithelial carcinoma. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:1239 / 1251
页数:13
相关论文
共 46 条
[1]   Metastasizing myxopapillary ependymoma [J].
Al-Hussaini, M ;
Herron, B .
HISTOPATHOLOGY, 2005, 46 (04) :469-470
[2]   Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems [J].
Alkushi, A ;
Abdul-Rahman, ZH ;
Lim, P ;
Schulzer, M ;
Coldman, A ;
Kalloger, SE ;
Miller, D ;
Gilks, CB .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (03) :295-304
[3]  
[Anonymous], 1971, Acta Obstet Gynecol Scand, V50, P1
[4]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[5]  
CRAMER SF, 1987, ARCH PATHOL LAB MED, V111, P819
[6]   Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential [J].
Crispens, MA ;
Bodurka, D ;
Deavers, M ;
Lu, K ;
Silva, EG ;
Gershenson, DM .
OBSTETRICS AND GYNECOLOGY, 2002, 99 (01) :3-10
[7]  
Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO
[8]  
2-T
[9]  
Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61
[10]   Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary [J].
Gershenson, David M. ;
Sun, Charlotte C. ;
Lu, Karen H. ;
Coleman, Robert L. ;
Sood, Anil K. ;
Malpica, Anais ;
Deavers, Michael T. ;
Silva, Elvio G. ;
Bodurka, Diane C. .
OBSTETRICS AND GYNECOLOGY, 2006, 108 (02) :361-368